About Fibronectin type 3 and ankyrin repeat domains protein 1
Fibronectin type 3 and ankyrin repeat domains protein 1 (FANK1) is a protein
from Homo sapiens identified by UniProt accession
Q8TC84, 345 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Fibronectin type 3 and ankyrin repeat domains protein 1 |
| UniProt accession | Q8TC84 |
| Gene | FANK1 |
| Organism | Homo sapiens |
| Length | 345 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- cortical surface area measurement · score 0.43
- blood protein measurement · score 0.40
- cortical thickness · score 0.32
- neuroimaging measurement · score 0.32
- brain measurement · score 0.31
- mean corpuscular hemoglobin · score 0.25
- mean corpuscular volume · score 0.22
- sitting height measurement · score 0.21
- Red cell distribution width · score 0.15
- body height · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TC84-F1 | alphafold | PREDICTED | 92.66 | — |
Amino-acid sequence (345 residues)
MEPQKIMPPS KPHPPVVGKV THHSIELYWD LEKKAKRQGP QEQWFRFSIE EEDPKMHTYG IIYTGYATKH VVEGLEPRTL YRFRLKVTSP SGECEYSPLV SVSTTREPIS SEHLHRAVSV NDEDLLVRIL QGGRVKVDVP NKFGFTALMV AAQKGYTRLV KILVSNGTDV NLKNGSGKDS LMLACYAGHL DVVKYLRRHG ASWQARDLGG CTALHWAADG GHCSVIEWMI KDGCEVDVVD TGSGWTPLMR VSAVSGNQRV ASLLIDAGAN VNVKDRNGKT PLMVAVLNNH EELVQLLLDK GADASVKNEF GKGVLEMARV FDRQSVVSLL EERKKKQRPK KSCVC
Explore Fibronectin type 3 and ankyrin repeat domains protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets